POSA150 Cost-Effectiveness Analysis of First-Line (1L) Systemic Treatments in Advanced Renal Cell Carcinoma (aRCC) in France
Abstract
Authors
S Tempelaar S Kroep L Marie L Juban M Kurt F Ejzykowicz JR May AF Gaudin N Dhanji S Branchoux